PTGS2 and cancer: Because chronic inflammation is directly involved with the overexpression of COX enzymes [49,50], this makes COX enzymes as viable therapeutic targets, especially COX-2, as it is predominantly overexpressed in a few cancer types (i.e., lung, colon, prostate, and breast) [51].